C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

OBJECTIVES:

- Determine the role of positron emission tomography using carbon-11 acetate (AC-PET) in
the initial and subsequent management of patients with prostate cancer at intermediate
or high risk for recurrence after initial curative therapy.

- Compare the value of AC-PET in predicting recurrence of prostate cancer with that of
conventional approaches (e.g., pre-operative clinical staging, prostate-specific
antigen, Gleason score, prostate and lymph node histology) in these patients.

Inclusion Criteria:

Male patients will be studied who have prostate cancer:

- Diagnosed with prostate adenocarcinoma

- Has completed conventional staging examinations, including histologic evaluation with
Gleason score, CT scan of the abdomen and pelvis, and whole-body bone scintigraphy
Candidate for curative prostatectomy OR curative radiotherapy OR staging
lymphadenectomy prior to surgery

- Deemed to be at intermediate or high risk for recurrence or metastatic disease after
initial curative treatment, as defined by of one of the following:

- Gleason score >= 7 or PSA >= 10

- Gleason score < 7 or PSA <10 ng/mL with positive surgical margins, biopsy proven
or suspected regional nodal involvement or conventional imaging showing limited
metastatic disease that may be amenable to directed radiotherapy

- Rising or non-responding PSA

Exclusion Criteria:

- < 18 years old

- claustrophobic patients